Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 18/20 | 0.66 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8737812 | 0.90 | RAF1 (0.69) | RAF1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL8737814 | 0.90 | RAF1 (0.67) | RAF1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL14402931 | 0.88 | RAF1 (0.68) | RAF1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL1846785 | 0.81 | RAF1 (0.64) | RAF1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL1846781 | 0.80 | RAF1 (0.63) | RAF1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL938435 | 0.80 | RAF1 (1.00) | RAF1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL1506293 | 0.79 | RAF1 (0.67) | RAF1MAPK13MAPK14KDRLMNA | |
| SCHEMBL1846665 | 0.79 | RAF1 (0.62) | RAF1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL1846663 | 0.79 | RAF1 (0.61) | RAF1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL1847101 | 0.78 | RAF1 (0.60) | RAF1MAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129893-A1 | Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas | DUMAS JACQUES (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129893-A1 | Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas | DUMAS JACQUES (US) | 2012-05-24 | — | — | US | disclosed |
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2007-10-18 | — | — | US | disclosed |
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BRAF, RAF1, ARAF | RAF1 2/4885MAPK13 90/4885MAPK12 245/4885 |
| US-20120129893-A1 | Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas | BRAF, RAF1, ARAF | RAF1 2/4885MAPK13 90/4885MAPK12 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.